Implications of ICS particle size on potential long-term asthma treatment-related side effects (e.g. metabolic and musculoskeletal comorbidities, pneumonia)

The aim of the study was to assess metabolic and other adverse consequences of small particle inhaled corticosteroids (ICS) and large particle ICS in patients with obstructive lung disease. Specifically to examine worsening control of pre-existing diabetes, risk of developing new-onset diabetes, change in BMI  and incidence of pneumonia; determining absolute rates and any dose-response relationships.

Lead Investigator:
Professor David Price
Research Team: Annie Burden, RiRL
Status: Active Study
Support: Teva
Documents and Publications:
Final Publications
Additional Material